Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

FAVOR III Europa Sub-Analysis: Coronary Revascularization Deferral Based On QFR vs FFR

When it comes to intermediate coronary lesion revascularization decision making, functional assessment is the recommended. At present, several indices are used, such as fractional flow reserve (FFR) and non-hyperemic coronary flow ratios. Among these, angiography based quantitative flow ratio (QFR), allows FFR estimation. Numerous studies have validated the use of QFR for coronary lesion revascularization decision making. 

However, the FAVOR III Europa randomized trial, published ad hoc, showed that QFR guided strategies do not reach non-inferiority vs FFR as regards major adverse cardiac events (MACE).

Even though revascularization deferral strategies based on physiological parameters have been shown safe for conventional indices, QFR safety has not yet been clearly established. 

Coronary Revascularization Strategies: QFR vs FFR in Intermediate Lesions

The aim of this Favor III Europa (randomized and multicenter) sub-analysis was to assess the safety of deferred revascularization based on QFR vs FFR. 

Read also: TENDERA: Comparing Conventional vs. Distal Transradial Occlusion for Coronary Interventions.

Primary end point was one-year MACE rate, defined as all-cause death, acute MI, or unplanned coronary revascularization. Secondary end point included individual primary end point components and target vessel failure (TVF).

The FAVOR III Europa trial included 2,000 patients, 1,008 assigned to QFR and 992 to FFR. Mean patient age was 66 and they were mostly men. The most frequent clinical presentation was chronic coronary syndrome.  

A total of 523 QFR patients (55.2%) and 599 FFR patients (65.3%) had at least one deferred revascularization. 433 of these QFR patients (82.8%) and 511 (85.3%) FFR patients had complete deferred revascularization of all lesions. In this subgroup, MACE rate was significantly higher among QFR patients vs FFR (24 [5.6%] vs 14 [2.8%]; HR 2.07; CI 95%: 1.07–4.03; p = 0.03). 

Read also: ROUTE TRAIL: DKCRUSH vs. DKRUSH Culotte in Non-Left Main Bifurcation Lesions.

In the subgroup of patients with at least one deferred lesion, MACE rate was 5.6% vs 3.6%, respectively (HR 1.55; CI  95%: 0.88–2.73; p = 0.13).

Conclusion: Impact of QFR vs FFR on Major Adverse Cardiac Events 

In this sub-analysis, QFR based deferred coronary revascularization was associated with higher MACE rate vs FFR. This difference was mainly related to an increase in unplanned revascularization. 

Original Title: Coronary revascularisation deferral based on quantitative flow ratio or fractional flow reserve: a post hoc analysis of the FAVOR III Europe trial.

Reference: Birgitte K. Andersen MD et al EuroIntervention 2025;21:e1-e10.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...